FDA Grants Breakthrough Therapy Designation to Merck’s Sacituzumab Tirumotecan for EGFR-Mutated NSCLC

Spur Therapeutics Unveils SPR301: A Novel Gene Therapy for GBA1-Linked Parkinson’s Disease

M | O | C Cancer Care & Research Centre Achieves CAR-T Therapy Milestone

Aptose Biosciences Collaborates with NCI to Advance Tuspetinib in Precision Medicine Trials for AML and MDS

Novartis and PTC Therapeutics Forge $2.9 Billion Partnership for Huntington’s Drug PTC518

HCG and Accenture Partner to Transform Cancer Care with Advanced AI

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics, Expanding Molecular Imaging Leadership in Asia

Strand Life Sciences Unveils CancerSpot for Early Cancer Detection

Allink Biotherapeutics Secures $42 Million in Series A Financing to Accelerate Development of Next-Generation Oncology and Immunology Therapies

Apollo Cancer Centres Launch India’s First Lunglife Screening Programme for Early Detection of Lung Cancer

Agilus Diagnostics Unveils Claudin 18.2 Test: A Breakthrough in Cancer Care

Leqembi® Launched in South Korea for Early Alzheimer’s Disease Treatment

QIAGEN Expands QIAstat-Dx Operations with New Facility in Barcelona

SunAct Cancer Institute Partners with Abgentil Biomedical to Revolutionize Cancer Treatment in India

Dr. Reddy’s Launches Toripalimab in India for Advanced Nasopharyngeal Carcinoma

Home
/
update
/
details

Agilus Diagnostics Unveils Claudin 18.2 Test: A Breakthrough in Cancer Care

NextEdge Admin

29 Nov 2024

2 min 39 sec

personalized medicine,Gastric cancer,Claudin 18.2

Agilus Diagnostics, India’s largest diagnostics network, has launched the Claudin 18.2 test, a revolutionary tool in cancer diagnostics. This innovative test represents a significant advancement in personalized medicine, offering critical support in the fight against gastric, pancreatic, and other cancers.

Gastric cancer, the fifth most common cancer among men and seventh among women in India, remains a leading cause of cancer-related deaths, particularly among individuals aged 15 to 44. The disease’s aggressive nature and limited treatment options underscore the importance of precise diagnostic tools like Claudin 18.2, which detects the presence of a key protein biomarker critical for targeted therapies.

The test aligns with recent FDA advancements, including the approval of zolbetuximab-clzb, a Claudin 18.2-targeted antibody therapy, and the VENTANA CLDN18 assay as a companion diagnostic. These developments empower oncologists to identify patients eligible for advanced treatments, enhancing therapeutic precision and improving patient outcomes.

Dr. Anand K., Managing Director & CEO of Agilus Diagnostics, highlighted the test’s transformative potential, stating, “Claudin 18.2 is a crucial biomarker in modern oncology, bridging the gap to personalized medicine. This test enables tailored treatments, improving outcomes and reinforcing our commitment to advancing diagnostics in India.”

Dr. Kunal Sharma, Associate Director & HOD, Histopathology, emphasized its significance in aligning Indian oncology with global innovations, providing advanced diagnostic and treatment opportunities.

By integrating AI-powered digital pathology and a focus on cutting-edge research, Agilus Diagnostics continues to lead in laboratory medicine, ensuring clinicians have the tools needed for precision care. The Claudin 18.2 test marks a pivotal step in enhancing cancer diagnosis, treatment, and survival rates, fostering a new era in Indian healthcare.